share_log

Maxim Group Initiates Coverage On Lexaria Bioscience With Buy Rating, Announces Price Target of $2

Maxim Group Initiates Coverage On Lexaria Bioscience With Buy Rating, Announces Price Target of $2

Maxim Group 以買入評級開始對 Lexaria Bioscience 進行報道,宣佈目標股價爲 2 美元
Benzinga ·  2023/07/21 22:00

Maxim Group analyst Michael Okunewitch initiates coverage on Lexaria Bioscience (NASDAQ:LEXX) with a Buy rating and announces Price Target of $2.

Maxim Group分析師Michael Okunewitch對Lexaria Bioscience(納斯達克:Lexx)進行了買入評級,並宣佈目標價為2美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論